ArticleBioconjugate chemistry
Direct identification of nonreducing GlcNAc residues on N-glycans of glycoproteins using a novel chemoenzymatic method.
Article in Bioconjugate chemistry. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 67 citations in OpenAlex.
- Scope of Microbial Transglutaminase for Site-Specific and Oriented Immobilization of Native Antibodies from Various Host Species.Langmuir : the ACS journal of surfaces and colloids · 2026Article
- First site-specific conjugation method for native goat IgG antibodies via glycan remodeling at the conserved Fc region.Antibody therapeutics · 2024Article
- Modulating antibody effector functions by Fc glycoengineering.Biotechnology advances · 2023Review
- Advances in chemical probing of proteinChemical Society reviews · 2021Review
- Precision Modification of Native Antibodies.Bioconjugate chemistry · 2021Review
- Generating orthogonal glycosyltransferase and nucleotide sugar pairs as next-generation glycobiology tools.Current opinion in chemical biology · 2021Review
- Molecular cargo in myeloid-derived suppressor cells and their exosomes.Cellular immunology · 2021Review
- Site-specific conjugation of native antibody.Antibody therapeutics · 2020Article
- Genetic recoding to dissect the roles of site-specific protein O-GlcNAcylation.Nature structural & molecular biology · 2019Article
- Glycoengineering of Antibodies for Modulating Functions.Annual review of biochemistry · 2019Review
- Identification ofFrontiers in endocrinology · 2019Article
- Imaging specific cellular glycan structures using glycosyltransferases via click chemistry.Glycobiology · 2018Article
- A Chemoenzymatic Histology Method for O-GlcNAc Detection.Chembiochem : a European journal of chemical biology · 2017Article
- Tools for Studying Glycans: Recent Advances in Chemoenzymatic Glycan Labeling.ACS chemical biology · 2017Review
- Surface Glycoproteins of Exosomes Shed by Myeloid-Derived Suppressor Cells Contribute to Function.Journal of proteome research · 2017Article
- Improved variants of SrtA for site-specific conjugation on antibodies and proteins with high efficiency.Scientific reports · 2016Article
- Pretargeted PET Imaging Using a Site-Specifically Labeled Immunoconjugate.Bioconjugate chemistry · 2016Article
- Glycosyltransferase engineering for carbohydrate synthesis.Biochemical Society transactions · 2016Review
- Article
- Strategies and Advancement in Antibody-Drug Conjugate Optimization for Targeted Cancer Therapeutics.Biomolecules & therapeutics · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
The mutant beta1,4-galactosyltransferase (beta4Gal-T1), beta4Gal-T1-Y289L, in contrast to wild-type beta4Gal-T1, can transfer GalNAc from the sugar donor UDP-GalNAc to the acceptor, GlcNAc, with efficiency as good as that of galactose from UDP-Gal. Furthermore, the mutant can also transfer a modified sugar, C2 keto galactose, from its UDP derivative to O-GlcNAc modification on proteins that provided a functional handle for developing a highly sensitive chemoenzymatic method for detecting O-GlcNAc post-translational modification on proteins. We report herein that the modified sugar, C2 keto galactose, can be transferred to free GlcNAc residues on N-linked glycoproteins, such as ovalbumin or asialo-agalacto IgG1. The transfer is strictly dependent on the presence of both the mutant enzyme and the ketone derivative of the galactose. Moreover, the PNGase F treatment of the glycoproteins, which cleaves the N-linked oligosaccharide chain, shows that the modified sugar has been transferred to the N-glycan chains of the glycoproteins and not to the protein portion. The application of the mutant galactosyltransferase, beta4Gal-T1-Y289L, to produce glycoconjugates carrying sugar moieties with reactive groups, is demonstrated. We envision a broad potential for this technology such as the possibilities to link cargo molecules to glycoproteins, such as monoclonal antibodies, via glycan chains, thereby assisting in the glycotargeting of drugs to the site of action or used as biological probes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.